Skip to main content

Articles

Cardiometabolic Health, Original Research
Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure
Chi Nguyen, PhD; Xian Zhang, PhD; Thomas Evers, PhD; Vincent J. Willey, PharmD; Hiangkiat Tan, MS, BPharm; Thomas P. Power, MD, FACC, MRCPI
Read More
Perspectives, Infectious Diseases
Are Nursing Homes COVID-19’s “Contaminated Wells,” and Will They Receive Additional Resources?
Bruce Pyenson, FSA, MAAA, and David C. Grabowski, PhD
Read More
Perspectives, Infectious Diseases
90 Days in 2020: COVID-19 Exposes Health Equity Opportunities
Byron C. Scott, MD, MBA
Read More
Perspectives
The Idealism of Youth
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports
Jean A. Gerlach; Brian Snow, PharmD; Katherine M. Prioli, MS; Ronald Vertsman, PharmD; Julie Patterson, PharmD, PhD; Laura T. Pizzi, PharmD, MPH
Read More
Foreword
Welcome to the Eleventh Annual Payers’ Guide to New FDA Approvals
Read More
FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
Loretta Fala
Read More
FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Loretta Fala
Read More
Page 30 of 244
Results 291 - 300 of 2434